Premium
Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis
Author(s) -
Takei Syuji
Publication year - 2002
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1046/j.1328-8067.2002.01535.x
Subject(s) - mizoribine , medicine , rheumatoid arthritis , lupus nephritis , clinical efficacy , arthritis , disease
Background: Mizoribine (MZR), isolated from culture medium of the mold, is a novel immunosuppressant developed in Japan. It has been used in patients with renal transplantation, lupus nephritis, nephrotic syndrome and rheumatoid arthritis (RA).Objectives: To review MZR in regards to mechanism of action, pharmacokinetics, efficacy and safety in the treatment of rheumatoid RA and juvenile idiopathic arthritis (JIA).Results: The drug MZR inhibits both humoral and cellular immunity in RA patients. It is completely excreted in the urine within 24 h, which contributes to the safety of MZR. A series of multicenter studies indicated that MZR was effective and safe in the treatment of RA. In JIA, however, there are only a few case reports reporting its efficacy and safety.Conclusion: A double‐blinded multicenter study is needed to establish the efficacy, safety and indication of MZR in the treatment of JIA.